Speaker illustration

Professor Jeroen Hendriks

Royal Adelaide Hospital, Adelaide (Australia)

Member of:

European Society of Cardiology
European Heart Rythm Association
Heart Failure Association

Professor Hendriks holds a Chair in Cardiovascular Nursing at Flinders University and the Royal Adelaide Hospital in Adelaide, Australia. He is also affiliated with the Centre for Heart Rhythm Disorders (Adelaide) and the Department of Medical and Health Sciences, Linköping University, Sweden. His doctoral studies focused on developing Integrated Care in terms of specialised AF-clinic. Over the past 10 years, he has developed an International reputation in the field of integrated care management of cardiac arrhythmias and associated conditions as well as the redesign of current practices and reform of health care systems. Currently, he is the President of the Australian Cardiovascular Health and Rehabilitation Association (SA/NT) and Deputy Chair of the Science Committee of ESC's ACNAP. He is the Past-president of the Dutch Society of CV Nurses and past Communication Officer of the ESC's CCNAP.

Patient simulations zone: management of arrhythmias (ACNAP Education)

Event: ACNAP-EuroHeartCare 2022

Topic: Arrhythmias, General

Session type: Special Session

Thumbnail

Great debate: do digital health interventions work for all cardiovascular patients?

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardiovascular Nursing and Allied Professions

Session type: Great Debates

Thumbnail

Patient/public involvement and advocacy matters!

Event: EuroHeartCare - ACNAP Congress 2021

Topic: Cardiovascular Nursing and Allied Professions

Session type: Symposium

Thumbnail

Allied health professional role development in arrhythmia diagnosis and management

Event: EHRA EUROPACE - CARDIOSTIM 2017

Topic: Nurse, Allied Professional, other

Session type: Symposium

Thumbnail

Clinical case session

Event: EuroHeartCare 2016

Topic: Miscellaneous

Session type: Clinical Cases

Thumbnail

This platform is supported by

logo Novo Nordisk